AccScience Publishing / AN / Online First / DOI: 10.36922/AN025160037
CASE SERIES

Lacosamide-induced myoclonus in patients with acute symptomatic metabolic seizures: A case series

Sherifa Ahmed Hamed1*
Show Less
1 Department of Neurology and Psychiatry, Assiut University Hospitals, Assiut, Egypt
Advanced Neurology, 025160037 https://doi.org/10.36922/AN025160037
Received: 17 April 2025 | Revised: 31 July 2025 | Accepted: 1 August 2025 | Published online: 4 September 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Fluid and electrolyte imbalances are common causes of seizures and admissions to intensive care units. This case series describes three female patients who experienced their first seizures. Case 1 was a 64-year-old woman with status epilepticus and severe hypocalcemia (6.8 mg/dL), who presented with generalized tonic–clonic (GTC), focal motor, and myoclonic seizures. Case 2 was a 70-year-old woman with cluster seizures, diagnosed with hypocalcemia (7 mg/dL) and hypomagnesemia (1.2 mg/dL), who also experienced GTC seizures. Case 3 was a 77-year-old woman with status epilepticus, diagnosed with dehydration, hyponatremia (120 mEq/dL), hypocalcemia (8 mg/dL), and hypokalemia (2 mEq/dL), who experienced complex partial seizures. Hospital management included intravenous fluids, electrolyte replacement, and antiseizure medications (ASMs) such as midazolam, levetiracetam, and phenytoin. Lacosamide, administered either to manage focal seizures or as an adjuvant ASM, induced myoclonic jerks, which resolved upon its discontinuation. After discharge, the patients received oral mineral and vitamin supplements and continued ASMs (levetiracetam, oxcarbazepine, and carbamazepine) for more than 3 months without seizure recurrence. In conclusion, this series emphasizes the potential for lacosamide to induce myoclonus in patients with electrolyte imbalances, potentially due to its specific action on sodium channels in the motor cortex.

Graphical abstract
Keywords
Lacosamide
Electrolyte disturbance
Metabolic seizures
Myoclonus
Funding
None.
Conflict of interest
The author declares no conflict of interest.
References
  1. DeLorenzo RJ, Towne AR, Pellock JM, Ko D. Status epilepticus in children, adults, and the elderly. Epilepsia. 1992;33 Suppl 4:S15-S25. doi: 10.1111/j.1528-1157.1992.tb06223.x

 

  1. LaRoche SM, Helmers SL. Epilepsy in the elderly. Neurologist. 2003;9(5):241-249. doi: 10.1097/01.nrl.0000087719.64343.be

 

  1. Castilla-Guerra L, del Carmen Fernández-Moreno M, López-Chozas JM, Fernández-Bolaños R. Electrolytes disturbances and seizures. Epilepsia. 2006;47(12):1990-1998. doi: 10.1111/j.1528-1167.2006.00861.x

 

  1. Kunze K. Metabolic encephalopathies. J Neurol. 2002;249(9):1150-1159. doi: 10.1007/s00415-002-0869-z

 

  1. Modi S, Tripathi M, Saha S, Goswami R. Seizures in patients with idiopathic hypoparathyroidism: Effect of antiepileptic drug withdrawal on recurrence of seizures and serum calcium control. Eur J Endocrinol. 2014;170(5):777-783. doi: 10.1530/EJE-14-0075

 

  1. Riggs JE. Neurologic manifestations of electrolyte disturbances. Neurol Clin. 2002;20(1):227-239, vii. doi: 10.1016/s0733-8619(03)00060-4

 

  1. Nigro N, Winzeler B, Suter-Widmer I, et al. Symptoms and characteristics of individuals with profound hyponatremia: A prospective multicenter observational study. J Am Geriatr Soc. 2015;63(3):470-475. doi: 10.1111/jgs.13325

 

  1. Hamed SA. Influences of bone and mineral metabolism in epilepsy. Expert Opin Drug Saf. 2011;10(2):265-280. doi: 10.1517/14740338.2011.534455

 

  1. Chisti MJ, Salam MA, Ashraf H, et al. Prevalence, clinical predictors, and outcome of hypocalcaemia in severely-malnourished under-five children admitted to an urban hospital in Bangladesh: A case-control study. J Health Popul Nutr. 2014;32(2):270-275. doi: 10.1371/journal.pone.0140327

 

  1. Nardone R, Brigo F, Trinka E. Acute symptomatic seizures caused by electrolyte disturbances. J Clin Neurol. 2016;12(1):21-33. doi: 10.3988/jcn.2016.12.1.21

 

  1. Glover M, Clayton J. Thiazide-induced hyponatraemia: epidemiology and clues to pathogenesis. Cardiovasc Ther. 2012;30(5):e219-226. doi: 10.1111/j.1755-5922.2011.00286.x

 

  1. Koppel BS. Treatment of acute and remote symptomatic seizures. Curr Treat Options Neurol. 2009;11(4):231-241. doi: 10.1007/s11940-009-0027-3

 

  1. Schwartzkroin PA, Baraban SC, Hochman DW. Osmolarity, ionic flux, and changes in brain excitability. Epilepsy Res. 1998;32(1-2):275-285. doi: 10.1016/s0920-1211(98)00058-8

 

  1. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press; 2010.

 

  1. Gloth FM, Gundberg CM, Hollis WB, Haddad JG, Tobin JD. Vitamin D deficiency in homebound elderly persons. JAMA. 1995;274(21):1683-1686. doi: 10.1001/jama.1995.03530210037027

 

  1. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ. 2008;336(7656):1298-1302. doi: 10.1136/bmj.39582.589433.BE

 

  1. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. doi: 10.1210/jc.2011-0385

 

  1. Herzig-Nichtweiß J, Salih F, Berning S, et al. Prognosis and management of acute symptomatic seizures: A prospective, multicenter, observational study. Ann Intensive Care. 2023;13(1):85. doi: 10.1186/s13613-023-01183-0

 

  1. Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189-205. doi: 10.1016/j.eplepsyres.2014.11.021

 

  1. Belcastro V, Arnaboldi M, Taborelli A, Prontera P. Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine. Epilepsy Behav. 2011;20(3):589-590. doi: 10.1016/j.yebeh.2011.01.022

 

  1. Swaminathan A, Kapoor S. A case report of exacerbation of myoclonus in idiopathic generalized epilepsy from use of lacosamide. Neurology. 2015;84(14 Suppl):P7.038.

 

  1. Birnbaum D, Koubeissi M. Unmasking of myoclonus by lacosamide in generalized epilepsy. Epilepsy Behav Case Rep. 2016;7:28-30. doi: 10.1016/j.ebcr.2016.09.006

 

  1. Wechsler RT, Yates SL, Messenheimer J, Leroy R, Beller C, Doty P. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension. Epilepsy Res. 2017;130:13-20. doi: 10.1016/j.eplepsyres.2016.12.015

 

  1. Abarrategui B, García-García ME, Toledano R, Parejo- Carbonell B, Gil-Nagel A, García-Morales I. Lacosamide for refractory generalized tonic-clonic seizures of non-focal origin in clinical practice: A clinical and VEEG study. Epilepsy Behav Case Rep. 2017;8:63-65. doi: 10.1016/j.ebcr.2017.08.001

 

  1. Szabó CA, Morgan LC, Sonnenberg S, Karkar KM. Absence status induced by lacosamide adjunctive therapy. Epilepsy Disorders. 2019;21(1):97-101. doi: 10.1684/epd.2019.1032

 

  1. Vossler DG, Knake S, O’Brien TJ, et al. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: A double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2020;91(10):1067-1075. doi: 10.1136/jnnp-2020-323524

 

  1. Bosak M, Wężyk K, Słowik A. Lacosamide and myoclonic seizures: What is the risk of aggravation? Neurol Neurochir Pol. 2021;55(1):107-109. doi: 10.5603/PJNNS.a2021.0008

 

  1. Vimpat: Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2018/022255s024lbl.pdf [Last accessed on 2025 Feb 12].

 

  1. Reynolds AS, Rohaut B, Holmes MG, et al. Early myoclonus following anoxic brain injury. Neurol Clin Pract. 2018;8(3):249-256. doi: 10.1212/CPJ.0000000000000466

 

  1. Chai Y, Bush AM, Coloigner J, et al. White matter has impaired resting oxygen delivery in sickle cell patients. Am J Hematol. 2019;94(4):467-474. doi: 10.1002/ajh.25423

 

  1. Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. Adv Neurol. 1986;43:629-643.

 

  1. Striano P, Manganelli F, Boccella P, Perretti A, Striano S. Levetiracetam in patients with cortical myoclonus: A clinical and electrophysiological study. Mov Disord. 2005;20(12):1610-1614. doi: 10.1002/mds.20530

 

  1. Merchant SHI, Vial-Undurraga F, Leodori G, van Gerpen JA, Hallett M. Myoclonus: An electrophysiological diagnosis. Mov Disord Clin Pract. 2020;7:489-499. doi: 10.1002/mdc3.12986

 

  1. Guerrini R, Mari F. Cortical myoclonus and epilepsy: Overlap and differences. In: ShorvonS, Pedley TA, editors. Blue Books of Neurology. Vol. 33., Ch. 8. United States: Butterworth-Heinemann; 2009. p. 97-118. doi: 10.1016/B978-1-4160-6171-7.00008-X

 

  1. Eberhardt O, Topka H. Myoclonic disorders. Brain Sci. 2017;7(8):103. doi: 10.3390/brainsci7080103

 

  1. Chandarana M, Saraf U, Divya KP, Krishnan S, Kishore A. Myoclonus- a review. Ann Indian Acad Neurol. 2021;24(3):327-338. doi: 10.4103/aian.AIAN_1180_20

 

  1. Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:133-139. doi: 10.1111/j.1528-1167.2005.00325.x

 

  1. Rissardo JP, Caprara ALF. Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: A literature review. Clin Neuropharmacol. 2020;43(3):66-80. doi: 10.1097/WNF.0000000000000387

 

  1. Hernandez CM, Richards JR. Physiology, sodium channels. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK545257

 

  1. Brefel-Courbon C, Gardette V, Ory F, Montastruc JL. Drug-induced myoclonus: A french pharmacovigilance database study. Neurophysiol Clin. 2006;36:333-336. doi: 10.1016/j.neucli.2006.12.003
Share
Back to top
Advanced Neurology, Electronic ISSN: 2810-9619 Print ISSN: 3060-8589, Published by AccScience Publishing